Table 1 Baseline characteristics of the prostate cancer patients after matching
ADT Nonusers (n = 273) | ADT users (n = 1019) | PS Matching | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
ADT nonusers (n = 272) | ADT users (n = 272) | |||||||||
Characteristic | n | % | n | % | p-value | n | % | n | % | p-value |
Age, mean SDa | 69.8 | 8.59 | 73.7 | 7.86 | < 0.001 | 69.8 | 8.59 | 70.3 | 8.71 | 0.488 |
Age stratification | < 0.001 | 0.978 | ||||||||
≤ 60 | 39 | 14.3 | 73 | 7.2 | 38 | 14.0 | 39 | 14.3 | ||
61–70 | 98 | 35.9 | 247 | 24.2 | 98 | 36.0 | 96 | 35.3 | ||
71–80 | 107 | 39.2 | 481 | 47.2 | 107 | 39.3 | 105 | 38.6 | ||
> 80 | 29 | 10.6 | 218 | 21.4 | 29 | 10.7 | 32 | 11.8 | ||
Comorbidity | ||||||||||
Diabetes mellitus | 50 | 18.3 | 221 | 21.7 | 0.224 | 50 | 18.4 | 47 | 17.3 | 0.737 |
Ischemic heart disease | 52 | 19.1 | 205 | 20.1 | 0.694 | 52 | 19.1 | 53 | 19.5 | 0.914 |
Congestive heart failure | 16 | 5.9 | 76 | 7.5 | 0.362 | 16 | 5.9 | 16 | 5.9 | 1.000 |
COPD | 59 | 21.6 | 249 | 24.4 | 0.331 | 59 | 21.7 | 53 | 19.5 | 0.525 |
Hypertension | 139 | 50.9 | 565 | 55.5 | 0.182 | 138 | 50.74 | 131 | 48.2 | 0.548 |
Dyslipidemia | 75 | 27.5 | 216 | 21.2 | 0.028 | 74 | 27.2 | 74 | 27.2 | 1.000 |
Thyroid disease | 6 | 2.2 | 17 | 1.7 | 0.557 | 6 | 2.2 | 5 | 1.8 | 0.761 |
Atrial fibrillation | 4 | 1.5 | 19 | 1.9 | 0.658 | 4 | 1.5 | 2 | 0.7 | 0.412 |
Liver disease | 32 | 11.7 | 117 | 11.5 | 0.912 | 32 | 11.7 | 32 | 11.7 | 1.000 |
Renal disease | 14 | 5.1 | 72 | 7.1 | 0.254 | 14 | 5.2 | 9 | 3.3 | 0.287 |
Comedications | ||||||||||
ACEIs | 34 | 12.5 | 158 | 15.5 | 0.281 | 34 | 12.5 | 38 | 14.0 | 0.613 |
ARBs | 34 | 12.5 | 163 | 16.0 | 0.148 | 33 | 12.1 | 43 | 15.8 | 0.216 |
Beta blockers | 76 | 27.8 | 261 | 25.6 | 0.457 | 75 | 27.6 | 70 | 25.7 | 0.628 |
CCBs | 108 | 39.6 | 419 | 41.1 | 0.642 | 107 | 39.3 | 100 | 36.8 | 0.537 |
Alpha blockers | 80 | 29.3 | 381 | 37.4 | 0.013 | 80 | 29.4 | 102 | 37.5 | 0.046 |
NSAIDs | 231 | 84.6 | 837 | 82.1 | 0.337 | 230 | 84.6 | 227 | 83.5 | 0.726 |
Statins | 46 | 16.9 | 122 | 12.0 | 0.033 | 45 | 16.5 | 37 | 13.6 | 0.338 |
Antiplatelet drugs | 52 | 19.1 | 207 | 20.3 | 0.643 | 52 | 19.1 | 49 | 18.0 | 0.741 |
Anticoagulants | 2 | 0.7 | 12 | 1.2 | 0.528 | 2 | 0.7 | 5 | 1.8 | 0.254 |
Antidiabetic drugs | 38 | 13.9 | 183 | 18.0 | 0.116 | 38 | 14.0 | 44 | 16.2 | 0.472 |